# Alector, Inc.: overview ALEC · Nasdaq · CIK 1653087 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/alec.md) · [Financials](/companies/alec/financials.md) · [Filings](/companies/alec/filings.md) · [Insiders](/companies/alec/insiders.md) Latest reported revenue: [$3.3m](/filings/0001193125-26-338052.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-338052). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [15.3](/filings/0001193125-25-269592.md) | [54.2 d](/filings/0001193125-26-071593.md) | [3.7](/filings/0001193125-26-211981.md) | [7.9](/filings/0001193125-26-338052.md) | [3.3](/filings/0001193125-25-269592.md) | [6.2 d](/filings/0001193125-26-071593.md) | [1.0](/filings/0001193125-26-211981.md) | [3.3](/filings/0001193125-26-338052.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(315.7%)](/filings/0001193125-25-269592.md) | [(13.4%) d](/filings/0001193125-26-071593.md) | [(1216.5%)](/filings/0001193125-26-211981.md) | [(433.6%)](/filings/0001193125-26-338052.md) | [(1153.6%)](/filings/0001193125-25-269592.md) | [(634.4%) d](/filings/0001193125-26-071593.md) | [(2382.3%)](/filings/0001193125-26-211981.md) | [(734.7%)](/filings/0001193125-26-338052.md) | | Net margin | % | [(275.2%)](/filings/0001193125-25-269592.md) | [(3.8%) d](/filings/0001193125-26-071593.md) | [(1101.6%)](/filings/0001193125-26-338052.md) | [(387.7%)](/filings/0001193125-26-338052.md) | [(1063.4%)](/filings/0001193125-25-269592.md) | [(597.5%) d](/filings/0001193125-26-071593.md) | [(2192.2%)](/filings/0001193125-26-338052.md) | [(692.5%)](/filings/0001193125-26-338052.md) | | Diluted EPS | $ per share | [(0.43)](/filings/0001193125-25-269592.md) | not reported | [(0.41)](/filings/0001193125-26-211981.md) | [(0.30)](/filings/0001193125-26-338052.md) | [(0.34)](/filings/0001193125-25-269592.md) | not reported | [(0.21)](/filings/0001193125-26-211981.md) | [(0.21)](/filings/0001193125-26-338052.md) | | Free cash flow | $m | [(50.9) d](/filings/0001193125-25-269592.md) | [(55.2) d](/filings/0001193125-26-071593.md) | [(60.8)](/filings/0001193125-26-211981.md) | [(49.1) d](/filings/0001193125-26-338052.md) | [(32.5) d](/filings/0001193125-25-269592.md) | [(41.7) d](/filings/0001193125-26-071593.md) | [(49.9)](/filings/0001193125-26-211981.md) | [(34.2) d](/filings/0001193125-26-338052.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [207](/filings/0000950170-24-021183.md) | [134](/filings/0000950170-25-027758.md) | [97.1](/filings/0000950170-25-027758.md) | [101](/filings/0001193125-26-071593.md) | [21.0](/filings/0001193125-26-071593.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(18.0%)](/filings/0000950170-24-021183.md) | [(103.2%)](/filings/0000950170-25-027758.md) | [(156.3%)](/filings/0000950170-25-027758.md) | [(144.2%)](/filings/0001193125-26-071593.md) | [(741.3%)](/filings/0001193125-26-071593.md) | | Net margin | % | [(17.5%)](/filings/0000950170-24-021183.md) | [(99.8%)](/filings/0000950170-25-027758.md) | [(134.3%)](/filings/0000950170-25-027758.md) | [(118.4%)](/filings/0001193125-26-071593.md) | [(679.2%)](/filings/0001193125-26-071593.md) | | Diluted EPS | $ per share | [(0.45)](/filings/0000950170-24-021183.md) | [(1.62)](/filings/0000950170-25-027758.md) | [(1.56)](/filings/0000950170-25-027758.md) | [(1.23)](/filings/0001193125-26-071593.md) | [(1.39)](/filings/0001193125-26-071593.md) | | Free cash flow | $m | [295](/filings/0000950170-24-021183.md) | [(24.4)](/filings/0000950170-25-027758.md) | [(187)](/filings/0000950170-25-027758.md) | [(231)](/filings/0001193125-26-071593.md) | [(184)](/filings/0001193125-26-071593.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/alec/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $20.1m | 10,000,000 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $15.8m | 7,847,879 | | Added +106,634 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $8.7m | 4,318,109 | | Added +1,502,126 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $8.7m | 4,318,109 | | Added +1,502,126 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $8.1m | 4,009,340 | | Added +330,618 | | [Kynam Capital Management, LP](/funds/1907884.md) | 2026-06-30 | $7.7m | 3,808,494 | | Added +1,808,494 | | [Merck & Co., Inc.](/funds/310158.md) | 2026-06-30 | $7.1m | 3,545,719 | | Unchanged | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $6.5m | 3,247,426 | | Added +312,173 | | [683 Capital Management, LLC](/funds/1404574.md) | 2026-06-30 | $6.4m | 3,200,000 | | Unchanged | | [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $5.9m | 2,959,983 | | Reduced −372,852 | ## Recent filings [All 615 filings](/companies/alec/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 16:47 ET | [8-K](/filings/0001193125-26-424204.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-424204 | | 2026-10-14 | 09:00 ET | [8-K](/filings/0001193125-26-421080.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-421080 | | 2026-10-05 | 07:00 ET | [8-K](/filings/0001193125-26-413090.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-413090 | | 2026-08-06 | 16:15 ET | [10-Q](/filings/0001193125-26-338052.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338052 | | 2026-08-06 | 16:10 ET | [8-K](/filings/0001193125-26-338008.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338008 | | 2026-07-08 | 16:05 ET | [8-K](/filings/0001193125-26-298526.md) | 1.02 Termination of a material agreement | 0001193125-26-298526 | | 2026-06-17 | 16:05 ET | [8-K](/filings/0001193125-26-274130.md) | 5.07 Shareholder vote results | 0001193125-26-274130 | | 2026-05-07 | 17:15 ET | [8-K](/filings/0001193125-26-212426.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-212426 | | 2026-05-07 | 16:17 ET | [10-Q](/filings/0001193125-26-211981.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211981 | | 2026-05-07 | 16:12 ET | [8-K](/filings/0001193125-26-211918.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211918 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-071593.md), filed Feb 25, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1653087 - Tickers: ALEC - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: not reported - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:19 ET. No prices; not investment advice.